Hypertrophic cardiomyopathy (HCM) affects> 600,000 patients in the United States, and
approximately 1 in 5 of them have atrial fibrillation (AF)(1). The incidence of stroke in …

Stroke prevention is the principal management priority in patients with nonvalvular atrial
fibrillation (AF) given its association with a 5-fold increase in stroke risk (1). Of note, AF is the …

Background Chronic anticoagulation is recommended in patients with hypertrophic
cardiomyopathy (HCM) and atrial fibrillation (AF). Non-vitamin K antagonist oral …

Hypertrophic cardiomyopathy (HCM) patients with nonvalvular atrial fibrillation (AF) have an
increased risk of suffering thromboembolic events. Vitamin K antagonists (VKA) are …

Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic
cardiomyopathy (HCM). 1 Prior literature reports a high incidence of thromboembolism in …

Background Chronic anticoagulation with vitamin K antagonists (VKAs) is recommended in
patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF). Direct oral …

Background There have been no prior nationwide reports on the prevalence of hypertrophic
cardiomyopathy (HCM) among patients suffering from atrial fibrillation (AF). It is also unclear …

Ischemic stroke (IS) is a catastrophic complication of hypertrophic cardiomyopathy (HCM)
with aging. We investigated the incidence of IS in HCM patients without atrial fibrillation (AF) …

Among the various non-ischaemic primary myocardial diseases recognized in humans, the
most common is hypertrophic cardiomyopathy (HCM). Though first recognized more than 60 …

Background and Purpose—Hypertrophic cardiomyopathy patients with atrial fibrillation are
at increased risk of stroke, and anticoagulation is strongly recommended. However, limited …